

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/189626 A2

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/47 (2006.01)
A61P 35/00 (2006.01) C07K 16/30 (2006.01)

(21) International Application Number:

PCT/EP2022/056332

(22) International Filing Date:

11 March 2022 (11.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21305299.6 11 March 2021 (11.03.2021) EP
22305237.4 02 March 2022 (02.03.2022) EP

(71) Applicants: **MNEMO THERAPEUTICS** [FR/FR]; 101 boulevard Murat, 75016 PARIS (FR). **INSTITUT CURIE** [FR/FR]; 26 rue d'Ulm, 75005 PARIS (FR). **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101, rue de Tolbiac, 75013 PARIS (FR).

(72) Inventors: **AMIGORENA, Sebastian**; 32 rue des cordeliers, 75013 PARIS (FR). **BURBAGE, Marianne**; 46 rue Myrha, 75018 PARIS (FR). **HOUY, Alexandre**; 17 rue Rosa Parks, 94400 Vitry sur Seine (FR). **WATERFALL, Joshua**; 4 rue d'Alleray, 75015 PARIS (FR). **STERN, Marc-Henri**; 41 rue Boulard, 75014 PARIS (FR). **SADACCA, Benjamin**; 271 rue de Belleville, 75019 Paris (FR). **MERLOTTI IPPOLITO, Antonela**; 144 avenue Parmentier, 75011 Paris (FR). **ARRIBAS DE SANDOVAL, Yagos**; 11D rue Marguerite de Rochechouart, 75009 Paris (FR). **GOUDOT, Christel**; 18 avenue Yves Carriou, 93150 LE BLANC MESNIL (FR).

(74) Agent: **PLASSERAUD IP**; 66 rue de la Chaussée d'Antin, 75440 PARIS CEDEX 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/189626 A2

(54) Title: TUMOR NEOANTIGENIC PEPTIDES

(57) Abstract: The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.